Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis

Esperion Therapeutics, Inc.

U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).
Collaboration revenue Q4 $124.7M (includes $90M Otsuka milestone); FY25 $243.6M (+12% Y/Y).
Q4 net income $61.8M ($0.26 basic EPS vs loss $0.11 in Q4 2024); FY25 net loss $22.7M narrowed from $51.7M.
Agreed to acquire Corstasis Therapeutics (Enbumyst nasal spray for CHF edema); targets $4B U.S. market.
Patent settlements restrict generic entry until April 2040; FY26 opex guidance $225-255M (incl ~$15M non-cash).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.